Abstract
Iodine-131 (131I) is a radioisotope used for the diagnosis and treatment of thyroidal disorders such as hyperthyroidism and cancer. During its decay, 131I emits beta particles and gamma rays; its physical half-life is 8 days, and it is accumulated preferentially in the thyroid tissue. This study aimed to evaluate the cytotoxicity and mutagenicity of diagnostic and therapeutic doses of 131I using bone marrow cells of rats treated in vivo in a test system with a single dose by gavage. Concentrations of 5, 25, 50 and 250 μCi in 1 ml of water were used, and after 24 h, the animals were killed. Also, a concentration of 25 μCi/ml of water was used, and the animals were killed after 5 days. The results showed that no concentration of 131I was cytotoxic and that all concentrations were mutagenic. As a result, there was no statistically significant difference detected by the χ2 test in the induction of chromosomal aberrations between the different doses. Thus, the present study demonstrated a significant increase in chromosomal aberration in bone marrow cells exposed to 131I regardless of the dose or the treatment time.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ballardin M, Gemignani F, Bodei L, Mariani G, Ferdeghini M, Rossi AM, Migliore L, Barale R (2002) Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutat Res 514:77–85
Barquinero JF, Barrios L, Caballin MR, Miro R, Ribas M, Subias A, Egozcue J (1993) Cytogenetic analysis of lymphocytes from hospital workers occupationally exposed to low levels of ionizing radiation. Mutat Res 286(2):275–279
Barrington SF, Anderson P, Kettle AG, Gadd R, Thomson WH, Batchelor S, Mountford PJ, Harding LK, O’Doherty MJ (2008) Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism. Eur J Nucl Med Mol Imaging 35:2097–2104
Calegaro JUM (2007) Baixos níveis de radiação ionizante causam câncer? Radiol Bras 40(4):9–10
Cardoso EM (2011) Apostila educativa: radioatividade. http://www.cnen.gov.br. Accessed 20 February 2011
Federico G, Boni G, Fabiani B, Fiore L, Lazzeri P, Massart F, Traino C, Verola C, Saggese G, Mariani G, Scarpato R (2008) No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving 131I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis. Eur J Nucl Med Mol Imaging 35:2113–2121
Ford CE, Hamerton JL (1956) A colchicine, hypotonic citrate, squash sequence for mammalian chromosome. Stain Technol 31:247–251
Gil OM, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, Léonard A, Gerber G, Rueff J (2000a) Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis 15(1):69–75
Gil OM, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, Rueff J (2000b) No evidence of increased chromosomal aberrations and micronuclei in lymphocytes from nonfamilial thyroid cancer patients prior to radiotherapy. Cancer Genet Cytogenet 123:55–60
Grawé J, Biko J, Lorenz R, Reiners C, Stopper H, Vershenya S, Vukicevic V, Hempel K (2005) Evaluation of the reticulocyte micronucleus assay in patients treated with radioiodine for thyroid cancer. Mutat Res 583:12–25
Gutiérrez S, Carbonell E, Galofré P, Creus A, Marcos R (1997) Micronuclei induction by 131I exposure: study in hyperthyroidism patients. Mutat Res 3731:39–45
Gutiérrez S, Carbonell E, Galofré P, Creus A, Marcos R (1998) Application of the single cell gel electrophoresis (SCGE) assay to the detection of DNA damage induced by 131I treatment in hyperthyroidism patients. Mutagenesis 13(1):95–98
Joseph LJ, Bhartiya US, Raut YS, Kand P, Hawaldar RW, Nair N (2009) Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis. Mutat Res 675(1–2):35–40
Natarajan AT (2002) Chromosome aberrations: past, present and future. Mutat Res 504:3–16
Plappert U, Raddatz K, Roth S, Fliedner TM (1995) DNA-damage detection in man after radiation exposure—the comet assay—its possible application for human biomonitoring. Stem Cells 13(1):215–222
Puerto S, Marcos R, Ramírez MJ, Galofré P, Creus A, Surrallés J (2000) Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine. Mutat Res 469:147–158
Reiners C, Labmann M (1999) Radioiodine (131I) treatment of hyperthyroidism: radiation protection and quality assurance. Eur J Nucl Med 26(7):683–685
Sapienza MT, Endo IS, Campos Neto GC, Tavares MGM, Marone MMS (2005) Tratamento do carcinoma diferenciado da tireóide com iodo-131: intervenções para aumentar a dose absorvida de radiação. Arq Bras de End e Met 49(3):341–349
Silva MA, Guimarães MICC, Yoriyaz H, Ribela MTCP, Buchpiquel CA, Bartoloni P, Okazaki K (2008) Evaluation of the cytogenetic effects of 131I preceded by recombinant human thyrotropin (rhTSH) in peripheral lymphocytes of Wistar rats. Radiat Environ Biophys 47:453–461
Sisson JC, Avram AM, Lawson SA, Gauger PG, Doherty GM (2006) The so-called stunning of thyroid tissue. J Nucl Med 47(9):1406–1412
Takahashi S, Thuy DTB, Sato H, Kubota Y, Sun XZ, Chandrasekharan NV (2000) Effects of the restriction of food and water intake on the distribution and retention of radioiodine in mice. J Radiat Res 41:313–320
Thrall JH, Ziessman HA (2003) Medicina Nuclear, 2nd edn. Guanabara Koogan, Rio de Janeiro, p 426p
Turgut B, Ozdemir O, Erselcan T (2006) Evaluation of the p53 tumor suppressor gene mutation in normal rat salivary gland tissue after radioiodine application: an experimental study. Adv Therapy 23(3):456–468
Watanabe N, Yokoyama K, Kinuya S, Shuke N, Shimizu M, Futatsuya R, Michigishi T, Tonami N, Seto H, Goodwin DA (1998) Radiotoxicity after Iodine-131 therapy for thyroid cancer using the micronucleus assay. J Nucl Med 39(3):436–440
Watanabe N, Kanegane H, Kinya S, Shuke N, Yokoyama K, Kato H, Tomizawa G, Shimizu M, Funada H, Seto H (2004) The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med 45(4):608–611
Acknowledgments
The authors would like to thank the Coordination for the Improvement of Higher Level Personnel—CAPES and the Laboratory of Cytogenetics and Mutagenesis staff of the State University of Maringá—UEM.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Düsman, E., Berti, A.P., Mariucci, R.G. et al. Mutagenicity of diagnostic and therapeutical doses of radiopharmaceutical iodine-131 in Wistar rats. Radiat Environ Biophys 50, 579–584 (2011). https://doi.org/10.1007/s00411-011-0380-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00411-011-0380-y